Sarepta Therapeutics, Inc. $SRPT Shares Sold by 683 Capital Management LLC

683 Capital Management LLC lowered its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 18.2% in the fourth quarter, Holdings Channel reports. The firm owned 810,000 shares of the biotechnology company’s stock after selling 180,000 shares during the quarter. Sarepta Therapeutics accounts for 0.8% of 683 Capital Management LLC’s investment portfolio, making the stock its 19th biggest holding. 683 Capital Management LLC’s holdings in Sarepta Therapeutics were worth $17,431,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently bought and sold shares of the business. Kestra Advisory Services LLC acquired a new stake in shares of Sarepta Therapeutics in the 4th quarter worth $25,000. iSAM Funds UK Ltd acquired a new stake in shares of Sarepta Therapeutics in the 3rd quarter worth $25,000. Ancora Advisors LLC lifted its stake in shares of Sarepta Therapeutics by 200.0% in the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 1,000 shares during the period. Allworth Financial LP increased its holdings in shares of Sarepta Therapeutics by 2,098.8% in the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 1,721 shares in the last quarter. Finally, Larson Financial Group LLC increased its holdings in shares of Sarepta Therapeutics by 82.5% in the 4th quarter. Larson Financial Group LLC now owns 1,882 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 851 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ SRPT opened at $16.96 on Thursday. The company has a market cap of $1.79 billion, a PE ratio of -17.67, a price-to-earnings-growth ratio of 0.17 and a beta of 0.21. Sarepta Therapeutics, Inc. has a 12 month low of $10.41 and a 12 month high of $25.32. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.63 and a quick ratio of 2.62. The company has a 50-day simple moving average of $18.81 and a 200-day simple moving average of $19.66.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $2.18. Sarepta Therapeutics had a negative net margin of 2.94% and a positive return on equity of 7.56%. The business had revenue of $730.80 million during the quarter, compared to the consensus estimate of $474.16 million. During the same period in the previous year, the firm posted ($3.42) earnings per share. The company’s quarterly revenue was down 1.9% compared to the same quarter last year. On average, equities analysts anticipate that Sarepta Therapeutics, Inc. will post 3.99 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Jefferies Financial Group reiterated a “buy” rating and issued a $30.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, March 3rd. Deutsche Bank Aktiengesellschaft increased their price target on shares of Sarepta Therapeutics from $12.00 to $14.00 and gave the company a “sell” rating in a report on Thursday, March 26th. Loop Capital set a $25.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, March 3rd. Royal Bank Of Canada raised their target price on shares of Sarepta Therapeutics from $18.00 to $19.00 and gave the company a “sector perform” rating in a report on Tuesday, April 7th. Finally, Oppenheimer restated an “outperform” rating and set a $37.00 target price on shares of Sarepta Therapeutics in a report on Thursday, March 19th. Eight investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and six have issued a Sell rating to the company. According to MarketBeat, Sarepta Therapeutics currently has an average rating of “Hold” and an average price target of $24.81.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.